In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

The pharmaceutical stock can still deliver.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Expanding Lilly’s U.S. manufacturing presence in Alabama will boost the Huntsville economy. For every dollar Lilly invests ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Notably, the Huntsville site will be among those that will manufacture orforglipron, Lilly’s first oral, small molecule GLP-1 ...

Major pharmaceutical manufacturer Eli Lilly and Company is building a $6 billion plant in the Tennessee Valley.

The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.